PROUS SCIENCE DRUG NEWS & PERSPECTIVES [455]

HOME : Support : Dialog Search Aids : Bluesheets
View Bluesheets by \| Database Name \| File Number \| Subject \| OneSearch Categories \| Search Options \|

	455
Prous Science Drug News & Perspectives

Last Loaded on Web: Monday, April 01, 2013

Last Update To Bluesheet: September 1, 2011

Bluesheet Contents PDF version

File Description	Dialog File Data	Special Features	Terms and Conditions	Additional Indexes	Rank
Subject Coverage	Document Types Indexed	DIALINDEX/OneSearch Categories	Sample Record	Limit	Predefined Format Options
Sources	Geographic Coverage	Contact	Basic Index	Sort	Rates

File Description [top]

The Prous Science Drug News & Perspectives database, produced by Prous Science Publishers, allows quick and easy consultation of the latest drug news. The Prous Science Drug News & Perspectives database contains all articles and texts published from selected sections (see Subject Coverage) of the printed journal, Prous Science Drug News & Perspectives , plus unpublished records from the journal's sections: "Line Extensions," "R&D Briefs," and "People on the Move." Unpublished records, omitted from the printed journal due to space limitations, are labeled "unpublished" and do not have volume, issue, or page numbers. Unpublished records may also include those in preparation for print. These records will have volume, issue and page numbers added in a later update to the database.

Subject Coverage [top]

The Prous Science Drug News & Perspectives database contains the following journal sections:

Discovery Line. A look at efforts in new drug discovery. Coverage: June 1993.
Licensing Line. Short summaries on new technology for licensing from various public and private sources. Coverage: January 1995 - September 2003.
Line Extensions. New uses, combinations and formulations of known drugs, including those launched and under development. Coverage: April 1993 - October 1994.
New Product Intros. New products recently launched on their first markets, including generic and brand names, action, indication, presentation, and source. Coverage: March 1995 - March 2004.
People on the Move. Organizational and personnel changes in the pharmaceutical industry. Coverage: January 1993 - November 1998.
R&D Briefs. Information on products progressing through the drug discovery and development pipeline throughout the world. Coverage: January 1992 - June 2005.
The Year's New Drugs. Annual articles that offer a historical and research perspective on new products that reached their first markets. A guide to developments in drug therapy, highlighting new generation compounds with therapeutic gains over existing drugs and new therapeutic entities arising from innovative approaches to drug research. Coverage: January 1988 - March 2004.

Sources [top]

The full-text entries in the Prous Science Drug News & Perspectives database are prepared from information compiled from current literature, conferences, company communications, and scientific contributions.

Dialog File Data [top]

Dates Covered:	January 1992 to 2005 (see "Subject Coverage" for coverage dates for each journal section).
File Size:	33,888 records as of November 2005
Update Frequency:	Closed

Document Types Indexed [top]

Journal Articles

Geographic Coverage [top]

International

Special Features [top]

ERA Available
KWIC and HILIGHT Available
DIALOG Alert Available
CURRENT Feature Available

DialIndex/OneSearch Categories [top]

ACRONYM	CATEGORY NAME
BIOBUS	Biosciences and Biotechnology Industry
DRUGECON	Pharmacoeconomics
PHARMIND	Pharmaceutical Industry News
PHARMR	Pharmacology + RINGDOC-Files
PROUS	Prous Science Publishers Files

Contact [top]

Prous Science Drug News & Perspectives is produced by Prous Science Publishers. Questions concerning file content should be directed to:

Prous Science
P.O. Box 540
Barcelona, 08080
Spain

Telephone:	+34 93 459-2220
Fax:	+34 93 458-1535
E-Mail:	service@prous.es

Terms and Conditions [top]

For Dialog's Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply.

(c)2000 J.R. Prous, S.A., All rights reserved. No part of this electronic database may be reproduced, abstracted, or transmitted in any form or by any means--electronic, mechanical, photocopying, recording, or otherwise--without the express written permission of the publisher, J.R. Prous, S.A. While great care has been taken in the preparation of this database, and the publisher has made a reasonable effort to supply complete and accurate information, it does not assume any liability for errors or omissions. J.R. Prous, S.A. makes no warranties, expressed or implied, with respect to the accuracy, quality, validity, or completeness of this database or the information therein or its merchantability or fitness for a particular purpose.

Dialog Standard Terms & Conditions apply.

SAMPLE RECORD [top]

The Year's New Drugs Section

	`DIALOG(R)File 455:Prous Science Drug News & Perspectives`
	`(c) 2000 J.R. Prous, S.A. All rts. reserv.`

	`00238215 (THIS IS THE FULLTEXT)`
/TI	`THE YEAR'S NEW DRUGS, 1993`
JN=, /SH, SH=	`Drug News & Perspectives, The Years New Drugs Section, v7, n1, p26`
PD=, PY=	`January 26 1994`
DT=, LA=, RT=	`DOCUMENT TYPE: Journal LANGUAGE: English RECORD TYPE: FullText`
	`WORD COUNT: 3,686`

/XT, /TX	`TEXT: Inaugurated six years ago, this annual section provides the`
	`opportunity to present from both a historical and a research`
	`perspective those molecular entities and biological drugs that`
	`were launched in various countries for the first time during the`
	`past year.`
	`Without exceeding space limitations, information on these`
	`drugs is presented to serve as a guide to the most recent`
	`developments in drug therapy, highlighting new-generation`
	`compounds with therapeutic gains over existing drugs and new`
	`therapeutic entities arising from innovative approaches to drug`
	`research. New indications for known drugs and new formulations`
	`are also included.`
/TX	`According to our records, 44 new molecular entities and`
	`biological drugs and 3 diagnostic agents first reached the market`
	`in 1993, a figure that represents a decrease with respect to the`
	`previous year (Table I). During the past year, antiinfective`
	`agents represented the most active group in terms of total`
	`launches, followed by central nervous system drugs. Japan was the`
	`most active market for new products, with a total of 21 launches`
	`in 1993, representing 49% of the total of new introductions for`
	`the year.`
	`(...)`
	`CENTRAL NERVOUS SYSTEM DRUGS`
	`Psychopharmacologic drugs`
	`Since the introduction of chlorpromazine in 1952, the`
	`dopamine D2 receptor has been the major target for antipsychotic`
	`drugs.`
	`(...)`
	`Neurologic drugs`
	`The cholinergic hypothesis of senile dementia proposes that`
	`aging is associated with a loss of cholinergic neurotransmission,`
	`which is essential for some cognitive functions. The cholinergic`
	`hypothesis has led to the development of compounds capable of`
	`improving cholinergic transmission within the CNS.`
	`(...)`
	`ANTIARTHRITIC DRUGS`
	`Two new NSAIDs were launched in Japan: ampiroxicam is`
	`marketed by Toyama (Nacyl) and Pfizer (Flucam), and the propionic`
	`acid derivative zaltoprofen was launched by Zeria (Peon) and`
	`Nippon Chemiphar (Soleton).`
	`RESPIRATORY DRUGS`
	`The potent H1-receptor antagonist emedastine difumarate was`
	`launched in Japan by Kowa (Remicut) and Kanebo (Daren) for the`
	`treatment of allergic rhinitis and urticaria.`
	`(...)`
	`CARDIOVASCULAR DRUGS`
	`Research on angiotensin-converting enzyme (ACE) inhibitors`
	`has resulted in the development of important new agents for the`
	`treatment of hypertension and heart failure.`
	`(...)`
	`RENAL-UROLOGIC DRUGS`
	`Torasemide (Boehringer Mannheim) is a sulfonylurea loop`
	`diuretic that was introduced last year in Germany (Unat) and`
	`Italy (Toradiur) and was approved in the U.S. (Demadex) for the...`
	`(...)`
	`DRUGS AFFECTING BLOOD COAGULATION`
	`Over the last decade, successful attempts have been made to`
	`fractionate and depolymerize heparin into fragments of various`
	`chain lengths. Low-molecular-weight heparins (LMWHs) inhibit...`
	`(...)`
	`ENDOCRINE DRUGS`
	`Prolactin, a hormone released from the anterior pituitary,`
	`regulates lactation. Dopamine D2 agonists have proven effective`
	`in preventing or suppressing puerperal lactation, as well as in...`
	`(...)`
	`METABOLIC DRUGS`
	`Osteoporosis is an important public health problem and is`
	`the cause of at least 1.2 million bone fractures in the U.S. each`
	`year. Two approaches toward bone mass manipulation have been...`
	`(...)`
	`GASTROINTESTINAL AGENTS`
	`As part of a program aimed toward discovering new antiulcer`
	`agents with enhanced cytoprotective activity, scientists at`
	`Tanabe Seiyaku synthesized a series of dehydroabietic acid...`
	`(...)`
	`DERMATOLOGIC DRUGS`
	`Betamethasone butyrate propionate (Antebate; Torii) was`
	`launched last year in Japan as a topical antiinflammatory`
	`corticosteroid.`
	`(...)`
	`IMMUNOLOGIC DRUGS`
	`A new vaccine that combines Lederle's diphtheria, tetanus`
	`and pertussis (DTP) vaccine (Tri-Immunol) with Praxis Biologics'`
	`Haemophilus b conjugate vaccine (HibTITER) was launched last year...`
	`(...)`
	`ANTIINFECTIVE AGENTS`
	`Thienamycin was isolated in 1979 from Streptomyces cattleya`
	`and was found to be highly active against almost all bacteria`
	`that are pathogenic in humans...`
	`(...)`
	`ANTINEOPLASTIC AGENTS`
	`Cladribine (Leustatin; Ortho Biotech) was launched last year`
	`in the United States as a single intravenous treatment for hairy`
	`cell leukemia, a rare, often fatal cancer of the blood and bone...`
	`(...)`
	`DIAGNOSTIC AGENTS`
	`Last year Shionogi launched Molecular Biosystems' Albunex`
	`injections, which are air-filled microspheres produced by`
	`sonication of human serum albumin, in Japan as a contrast agent...`
	`(...)`
	`...Radioisotope for the diagnosis of neuroblastoma, neurocytoma and`
	`medullary cancer of the thyroid.`
	`Copyright (c) 1994 J.R. Prous. All rights reserved.`

R&D Briefs Section

	`DIALOG(R) File 455: Prous Science Drug News & Perspectives`
	`(c) 2000 J.R. Prous, S.A. All rts. reserv.`

	`00268003 (THIS IS THE FULLTEXT)`
/TI	`MEDAREX BEGINS PHASE I/II TRIAL of MDX-210 WITH G-CSF`
JN=, /SH, SH=	`Drug News & Perspectives, R&D Briefs Section, v7, n8, P 485`
PD=, PY=	`September 29 1994`
DT=, LA=, RT=	`DOCUMENT TYPE: Journal LANGUAGE: English RECORD TYPE: Fulltext`
	`WORD COUNT: 134`

/XT, /TX	`TEXT: Medarex Inc. announced September 8, 1994, the initiation of`
	`a phase I/II clinical trial to evaluate MDX-210, the company's`
	`Bispecific(TM) antibody-based therapeutic for the treatment of`
	`breast cancer, in combination with granulocyte colony-stimulating`
	`factor (G-CSF).`
	`Preclinical studies indicated that this combination therapy`
	`may have the potential to increase the antitumor activity already`
	`observed in initial phase I/II clinical trials of MDX-210.`
	`Approximately 20 patients with demonstrated resistance to`
	`conventional treatments for breast cancer will be enrolled in the`
	`trial. The phase I/II will be conducted at the University of`
	`Erlangen, Germany, under the direction of Roland Repp, M.D., one`
	`of the investigators who led the preclinical studies of the`
	`combination therapy. The goal of the phase I/II trial is to`
	`evaluate the safety and optimal biological dose of MDX-210 in`
	`combination with G-CSF.`
	`Copyright (c) 1994 J.R. Prous. All rights reserved.`

BASIC INDEX [top]

SEARCH SUFFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
None	None	All Basic Index Fields	Word	S BREAST(W)CANCER
/SH	SH	Section Heading¹	Word	S R(W)D(W)BRIEFS/SH
/TI	TI	Title	Word	S MDX(W)210/TI
/TX	TX	Text	Word	S BREAST(W)CANCER/TX
/XF	None	All Basic Index Fields Except Full Text	Word	S BISPECIFIC/XF
/XT	XT	Extract	Word	S CLINICAL(W)TRIAL/XT

¹Searchable in the Basic Index and in the Additional Indexes.

ADDITIONAL INDEXES [top]

SEARCH PREFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
None	AZ	DIALOG Accession Number
None	CG	Article Copyright
DT=	DT	Document Type	Phrase	S DT=JOURNAL
JN=	JN	Journal Name	Phrase	S JN=DRUG NEWS & PERSPECTIVES
LA=	LA	Language³	Phrase	S LA=ENGLISH
PD=	PD	Publication Date	Phrase	S PD=19940126
PY=	PY	Publication Year	Phrase	S PY=1994
RT=	RT	Record Type⁴	Phrase	S RT=FULLTEXT
SH=	SH	Section Heading¹	Phrase	S SH=R&D BRIEFS
None	SO	Source Information²
UD=	None	Update	Phrase	S UD=9999
None	WD	Word Count

²Display Includes journal name, section, volume, issue, pagination, and publication date.

³All records are in English.

⁴All records are full-text.

LIMIT [top]

SUFFIX	FIELD NAME	EXAMPLES
/ENG	English-Language Articles³	S S1/ENG
/FULLTEXT	Full-Text Records⁴	S ACE(W)INHIBITOR?/FULLTEXT
/LONG	Word Count of 1,000 words or more	S S2/LONG
/SHORT	Word Count of less than 1,000 words	S S5/SHORT
/YYYY	Publication Year	S CHOLINERGIC/2004

SORT [top]

SORTABLE FIELDS	EXAMPLES
JN, PD, PY, TI	SORT S1/ALL/PY,D PRINT S5/5/1-24/TI

RANK [top]

RANK FIELDS	EXAMPLES
All phrase- and numeric-indexed fields in the Additional Indexes can be ranked.	RANK PY RANK SH S4

USER-DEFINED FORMAT OPTIONS [top]


Display codes listed in the Search Options tables can be used to customize output.	TYPE S3/TI,PD/1-5

PREDEFINED FORMAT OPTIONS [top]

NO.	DIALOGWEB FORMAT	RECORD CONTENT
1	--	DIALOG Accession Number
2	--	Bibliographic Citation and Word Count
3	Medium	Bibliographic Citation and Word Count
4	--	Bibliographic Citation, Word Count, and Extract
5	Long	Bibliographic Citation, Word Count, and Extract
6	--	Title, Publication Date, and Word Count
7	--	Bibliographic Citation and Text
8	Free	Title, Publication Date, and Word Count
9	Full	Full Record
K	--	KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats

DIRECT RECORD ACCESS [top]

FIELD NAME	EXAMPLES
If the accession number of a specific record is known, it can be used to display the record directly.	TYPE 00238215/5 DISPLAY 00238215/TI,TX PRINT 00238215/9

Rates [top]

Rates For File: Prous Science Drug News & Perspectives[455]
Cost per DialUnit:                $10.07
Cost per minute:                   $4.07
Rank Elements                      $0.00

Format    Types   Prints
     1    $0.00    $0.00
     2    $5.00    $5.00
     3    $5.00    $5.00
     4    $9.00    $9.00
     5    $9.00    $9.00
     6    $0.00    $0.00
     7    $9.00    $9.00
     8    $0.00    $0.00
     9    $9.00    $9.00
KWIC95    $1.25       NA
KWIC96    $1.25       NA

REDIST/COPY Multiplier Table:

      Range      Multiplier
        1-2       1.00
       3-25       1.50
     26-100       3.00
    101-200       4.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00

ARCHIVE Multiplier Table:

      Range      Multiplier
       1-25       1.50
     26-200       3.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00

[top]